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Abstract
Background Despite appropriate antiseizure drug (ASD) treatment, around two- thirds of dogs with 
idiopathic epilepsy (IE) have seizures long- term and –per cent of aected dogs remain poorly controlled.
Methods The current study aim is to test in a eld trial the ecacy and tolerability of a commercially 
available diet enriched with .per cent medium chain 
triglyceride (MCT) oil in dogs (n=) with at least a tier  
idiopathic epilepsy diagnosis, without cluster seizures, 
in  veterinary practices across Europe. Each dog’s 
quality of life (QoL), ataxia, sedation and frequency and 
severity of seizures were recorded by owners throughout 
the study.
Results The mean seizure frequency per month, 
averaged over the entire - day study, signicantly 
(P=.) decreased per cent compared with the 
baseline monthly seizure frequency recorded during the 
month immediately before feeding the diet. Similarly, 
the seizure days rate (days/month) also declined 
(P<.) by per cent. QoL was reported as very 
good to excellent (>./) in  of the  dogs before 
starting the diet and this remained unchanged during 
the trial.
Conclusions This study demonstrates the use of a diet 
enriched with MCTs as an adjunct to ASD treatment may 
have some antiseizure properties for dogs diagnosed 
with IE, as demonstrated in previous studies.
Introduction
Epilepsy is a common, chronic neurological disease  
affecting between .per cent and .per cent of dogs 
in the general population with a higher prevalence 
in some at- risk breeds.–  Epilepsy is defined as two 
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or more unprovoked epileptic seizures occurring 
at least  hours apart.   Idiopathic epilepsy (IE)  
is the most common form and can be a serious  
condition in dogs stemming from underlying genetic 
abnormalities especially in specific dog breeds, but 
also occurs where the underlying cause could not be 
identified.–   Unfortunately, IE not only affects the  
pet’s general health, but also quality of life (QoL).– 
A recent review paper highlighted that dogs with 
epilepsy are at risk not only for reduced QoL but also 
quantity of life.  QoL can be considered diminished  
in some epileptic dogs, as similarly experienced 
by people, with the development of comorbidities 
such as anxiety, hyperactivity disorders, cognitive  
impairments and antiseizure drug (ASD) side 
effects.– QoL of owners of epileptic dogs can also be 
reduced due to worries about their dog’s health and 
limitations in lifestyle to accommodate their epileptic 
pet.
The disease in many cases has an early onset (with 
most dogs having their rst seizure between one and 
three years of age) and is generally lifelong, typically 
requiring long- term use of ASDs,–  with the aim of 
reducing seizure frequency and severity. Unfortunately, 
–per cent of patients do not respond adequately to 
medical management, which can impact QoL. From a 
medical perspective, a reduction in seizure frequency of 
at least per cent is commonly considered a successful 
treatment. For these reasons, there is great interest in 
nding alternative and/or adjunct treatments for canine 
IE.
Dietary support has long been used in seizure 
management in people and a recent review describes 
how metabolic dysregulation appears to increase the 
probability of sporadic seizure activity. As early as the 
s, it was noted that epileptic children experienced a 
reduction in seizure frequency when they were fasted. 
In order to mimic the metabolic changes associated with 
fasting, ketogenic diets have been used with some success 
in epileptic people. One study showed that children with 
epilepsy put on a traditional ketogenic diet (high fat, 
low carbohydrate, low protein—starting at a : ratio—
fat:protein and carbohydrate—and gradually increasing 
to a : or : ratio over – weeks, as tolerated) had 
signicant seizure reduction compared with children 
on a control diet. The  per cent of children had > 
per cent seizure reduction and  per cent children had 
more than  per cent reduction in seizures (compared 
with  per cent and  per cent, respectively of children 
fed the control diet).  Dietary change is highly relevant 
to owners of epileptic dogs with a very recent survey 
containing  valid responses, two- thirds of owners 
(. per cent) reported changed their dog’s diet aer 
receiving an IE diagnosis. Nearly half of the owners 
(. per cent) reported giving dietary supplements, 
the most common being coconut oil or derived medium 
chain triglyceride (MCT) oil (. per cent).
More recently, a diet based on inclusion of 
MCTs was evaluated in epileptic dogs.  Although 
the exact mechanism of action of MCTs is not fully 
known, proposed mechanisms include provision 
of an alternative energy supply to the brain (energy 
metabolism is insucient in epileptic dogs), global 
changes in lipid metabolism and eects on cerebral 
neurotransmitters.–  The randomised, placebo- 
controlled, double- blinded, crossover study revealed 
that most dogs fed the test diet (containing MCT oil) 
for  days showed a reduction in seizure frequency. 
In this study,  per cent of dogs experienced reduced 
seizure frequency, with  per cent having a ≥ per 
cent reduction in seizure frequency and  per cent of 
dogs achieving complete seizure freedom. The positive 
eect of an MCT- enriched diet was also highlighted in a 
recent study comparing an MCT oil dietary supplement 
to a control oil (olive oil) in  dogs with IE being treated 
with standard ASD(s). Overall seizure and seizure- day 
frequency were signicantly lower in dogs that had the 
MCT oil dietary supplement added to their routine diet 
compared to dogs that had the control oil added to their 
food. Similar to the study by Law and others, , 
 per cent of dogs improved, and  per cent had 
more than  per cent reduction in seizure frequency, 
although only  per cent became seizure free.
Over recent years, it has become apparent that 
the mechanism of action of the traditional ketogenic 
diets, as well as diets containing MCTs, goes beyond 
ketone production.  Medium chain fatty acids are 
ecient in crossing the blood- brain barrier,  unlike 
long chain fatty acids, and can be directly oxidised 
in the brain.  In rats ketogenic diets may increase 
mitochondrial function and brain energy reserves. In 
addition, an MCT diet has been shown to dramatically 
increase mitochondrial function in dogs,  and also 
to increase metabolic synthesis of polyunsaturated 
fatty acids (PUFA) and their uptake in the canine brain 
tissue.  Interestingly, MCTs and their downstream 
metabolites are thought to have multiple aects in the 
brain.   Recent studies have revealed that decanoic 
acids (C) can act as a non- competitive AMPA receptor 
antagonist resulting in direct inhibition of excitatory 
neurotransmission, and thus exerts an anticonvulsant 
eect.  Furthermore, C on its own might be able to 
modulate mitochondrial proliferation via peroxisome 
proliferator- activated receptor gamma receptor.
Cluster seizures are known to be a risk factor for drug- 
resistant epilepsy.  The two aforementioned canine 
clinical studies   had a high proportion of dogs with 
cluster seizures. Thus, in the current investigation 
it was determined that including a high proportion 
of dogs with cluster seizures could potential bias the 
results regarding the diet eect. No study had formerly 
looked at the eect of MCTs on a population of dogs 
without cluster seizures. Hence, the eect was assessed 
in this subpopulation of patients. The objective of this 
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Table  Nutrient composition of the diet (as fed basis)
Nutrient Value
Moisture (%) .
Crude fat (%) .
Crude protein (%) .
Carbohydrates (%) .
Crude fibre (%) .
Crude ash (%) .
Chloride (%) .




MCT oil (%)* .
Energy value (kcal/g) .
*MCT oil .% added to the recipe (as is).
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; MCT, medium chain triglyceride.
prospective study was therefore to test the ecacy, 
palatability and tolerability of a commercially available 
diet enriched with . per cent MCT oil in dogs 
diagnosed with IE with single seizures across Europe. 
This study will further clarify the role of nutrition in 
epilepsy management.
Materials and methods
A prospective open- label, single- arm food study with 
no placebo was carried out across Europe (France, 
Italy, Poland, Portugal, Spain and Switzerland) with 
 veterinary practices. Study protocol was designed 
and followed in strict accordance with the guidelines 
established by the Nestlé Purina PetCare Animal Care 
and Use Advisory Committee. All dogs were privately 
owned and were enrolled only after owner consent was 
obtained. The aim of the study was to investigate the 
efficacy and tolerability of a commercially available 
veterinary prescription- based diet containing . per 
cent of MCT oil (Purina Pro Plan NC NeuroCare, Nestlé 
Purina, St. Louis Missouri, USA) for the management of 
dogs diagnosed with IE. Proximate analyses results of 
the diet are listed in table.
Twenty- two dogs diagnosed with IE, which had no 
reported events of cluster seizures, were recruited and 
included in the trial based on multiple criteria; aged 
between  months (small and medium dogs)/ 
months (large dogs) and  years old, with a maximum 
bodyweight (BW) of  kg and with a tier  IE diagnosis. 
In addition, dogs must have experienced at least three 
seizures in the three months before inclusion and must 
have been treated with at least one antiepileptic drug 
for a minimum of one year before inclusion. Finally, pet 
owners must have been in full agreement to their dogs 
taking part in the study.
Dogs were not included in the study if they had 
another identiable cause of their seizures (eg, brain 
neoplasm, brain trauma, etc), were experiencing 
cluster seizures (more than one seizure per day), had 
concomitant diseases such as liver, kidney or heart 
conditions or had surgery in the month before inclusion 
(or if surgery was planned during the study period). 
Pregnant or lactating females and dogs over  kg were 
also excluded from the study.
The breed, gender, age, diet and lifestyle of each dog 
were recorded during the inclusion appointment. A full 
history was taken including seizure frequency during 
the past  days to establish baseline monthly seizure 
rate, concomitant disease and treatments given. Dogs 
accepted into the trial had an initial clinical examination 
including body condition score (BCS) assessed using 
a - point scale,  BW, rectal temperature and general 
health status evaluation. Owner evaluations were 
made of the dog’s QoL, ataxia, sedation and frequency 
and severity of seizures using a visual analogue scale 
as previously described  (see online supplementary 
gure ). Dogs being treated with phenobarbital and/
or potassium bromide (KBr) had blood collected during 
the inclusion appointment ve hours aer the ASD 
administration to monitor serum drug concentrations.
Owners who gave permission for their dog to 
participate in the study, were requested to change their 
dog onto the study diet (Purina Pro Plan NC NeuroCare) 
gradually over a seven- day period so that by day  the 
dogs were eating  per cent of the recommended 
amount of the study diet and nothing else other than 
free- access water to drink. The feeding amount was 
initially advised as described per the product label 
feeding instruction, with daily amounts determined 
according to metabolic energy requirements calculated 
according to the European Pet Food Industry Federation 
(FEDIAF) recommended energy equation of  
kcal×BW.. Each clinician had the liberty to adjust 
daily recommended portion based on individual pet’s 
home climate conditions, the pet’s physical activity and 
physical health condition. Depending on the BW and 
animal health status in the rst month visit, the amount 
was adjusted to ensure the BW and BCS maintenance. 
Daily feeding frequency (once or multiple meals daily) 
was at the discretion of the pet owner. Purina Pro Plan 
NC NeuroCare was recommended to be provided as 
treats or snacks.
Follow- up visits were performed at day ,  and 
. At each follow up visit, a clinical examination 
(including BCS, BW, rectal temperature and general 
health status evaluation) was performed, as well  
as the ASD dose administered and its possible side  
eects were recorded. The owners also evaluated the 
dog’s QoL, ataxia, sedation and diet consumption, as 
well as frequency and severity of seizures along with 
global evaluation of the diet’s ecacy and tolerance 
each month as described previously.  Throughout 
the study, owners were also asked to record days  
when their dog experienced a seizure and number  
and duration of seizures experienced during that  
day. Similar to day  visit, dogs being treated with 
phenobarbital and/or KBr had blood collection ve 
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Average % food 
consumed over 
trial
Number of seizure days/month Seizure frequency/month
Baseline
End of 
trial % change Baseline
End of 
trial % change
  F  Cocker spaniel PKBr .  . −. . −.
   Mixed setter SF PI .  . −. . −.
 P  Mixed breed . SM   . −. . −.
   Dachshund SM PKBr .  . −. . −.
 M  Dachshund  PKBr .  . −. . −.
  M I  Beagle .  . −. . −.
 Crossed Griffon   . −. . −. ISM  
  M P  Mixed breed .  . −. . −.
  M  Labrador retriever PKBr   . −. . −.
 Belgian shepherd .   . −. . −.SF P  
 Giant schnauzer PKBr .  . −. . −. SM  
 .  . −. . −.Poodle  M I  
 Crossbreed .  . −. . −. F I  
 Labrador retriever .  . −. . −. F I  
 Crossbreed PL .  . −. . −. F  
 Labrador retriever PI   . −. . −. M  
 English setter PL .  . . . . SM  
 Shih Tzu   . . . . M P LT  
 Crossbreed .  . . . . M P  
 Crossbreed   . . . . M P  
 Irish setter   . . . . M P LT  
*Sex and intact status.
F, female; I, imepitoin; KBr, potassium bromide; L, levetiracetam; M, male; P, phenobarbital; S, sterile; T, topiramate.
Table  Effect of the diet in all dogs (n=) and only dogs that experience
single seizure events per day (n=) for each of the measurements 
(mean±se) between baseline and the end of the study





BW (kg)  . (±.) . (±.) .
BCS  . (±.) . (±.) .
N° of seizure days/month  . (±.) . (±.) <.
Total n° of seizures/month  . (±.) . (±.) .
BW (kg)  . (±.) . (±.) .
BCS  . (±.) . (±.) .
N° of seizure days/month  . (±.) . (±.) <.
Total n° of seizures/month  . (±.) . (±.) <.
BCS, body condition score; BW, bodyweight; n°, number.
hours aer the ASD administration to monitor serum 
drug concentrations.
At the end of the study period ( weeks), records 
were taken on the pet owner’s perception of the 
palatability and eectiveness of the food and whether or 
not they would recommend it for use by other epileptic 
dogs. The participating veterinarians were asked to also 
record whether or not they would recommend the dog 
to continue on the test diet for long term.
Statistical analysis
Data were analysed using R lme software package. 
All analyses were conducted using R (V..., accessed 
September , ).  The dog was considered the 
experimental unit for all analyses. To compare the BW, 
BCS and seizure frequency between the starting point 
and the day  (end of study), a Wilcoxon rank-  sum 
statistical test (non- parametric paired test) was 
performed. Seizure frequency refers to the number of 
seizures per month, and seizure day rate refers to the 
number of days in a month with seizure occurrence. 
A P value <. was considered to be statistically 
significant.
Results
Data were collected from  dogs (table ) including 
 pure breeds (dachshund, Belgian shepherd, English 
setter, cocker spaniel, poodle, Labrador retriever, giant 
schnauzer, beagle, Maltese, Irish setter, Shih Tzu), and 
 mixed breed dogs table. A single dog (. years old, 
female Maltese) was removed from the analysis because 
of lack of test food ingestion ( per cent of ration 
during month two:  per cent of ration during month ). 
Of the remaining  dogs, the median age was . years 
old (range: – years) and the gender distribution was 
 (. per cent) entire females,  (. per cent) spayed 
females,  (. per cent) entire males and  (. 
per cent) neutered males. No significant difference was 
observed for BW (P=.) and BCS (P=.) change 
during the trial period (table).
Of the  dogs,  dogs continued to only have 
single seizure events on a given day during the entire 
test period, whereas  dogs experienced either  or  
cluster seizures, and  dogs had no seizures observed. 
Acceptance of the food was good (> per cent of ration) 
to excellent ( per cent of ration) in  out of the  
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As a result of feeding the diet for  days, the mean 
seizure day rate signicantly declined (P=.) by 
 per cent (. seizure days/month; median=.) 
compared with the baseline (. days/month; 
median=.) (table ). At baseline, seizure days/
month ranged from a minimum of one to a maximum 
of six, whereas aer the diet phase it ranged from  to 
a maximum of . days/month. Of the  dogs, . 
per cent ( of  dogs) became seizure free, . per 
cent of dogs ( of  dogs) had ≥ per cent reduction 
in seizure days and . per cent ( of  dogs) had < 
per cent reduction. In addition, three dogs (. per 
cent) had no change, whereas two dogs (. per cent) 
had an increase in seizure days. Overall,  of  dogs 
(. per cent) experienced fewer seizure days with the 
test diet.
For total seizure frequency, feeding the diet resulted 
in a  per cent decline (P=.) (. seizures/month: 
median=.) compared with baseline (. seizures/
month; median=.; table ). Generally similar to 
seizure day rate, the relative proportion of dogs that 
became seizure free was . per cent ( dogs), . per 
cent had ≥ per cent reduction ( dogs) and . per 
cent ( of  dogs) had < per cent reduction. One dog 
(. per cent) had no change and four dogs (. per 
cent) had an increase in seizure frequency. Overall,  
of  dogs (. per cent) experienced a lower seizure 
frequency with the test diet.
Aer reviewing the seizure data for each dog, ve 
dogs had experienced at least one cluster seizure during 
the trial phase. Of these ve dogs, there was no apparent 
pattern in the occurrence of the cluster seizures while 
on the test diet. A post hoc statistical analysis was 
performed that excluded the ve dogs that experienced 
cluster seizures at some point during the treatment 
period (table ) because the aim of the study was to 
especially study its eects on dogs with single seizures. 
The mean seizure day rate (. seizure days/month) for 
the test phase signicantly (P<.) declined by  per 
cent compared with the baseline seizure day rate (. 
days/month) for  non- cluster seizure dogs. None of 
these  dogs had any worsening of seizure day rate or 
seizure frequency ( per cent) and . per cent of dogs 
( of ) were seizure- free throughout the entire - day 
feeding trial. Overall, . per cent of dogs ( of ) 
had greater than a  per cent reduction in seizure days 
and seizure frequency, with . per cent of dogs ( of 
) experiencing greater than a  per cent reduction 
in seizures. Only two dogs (. per cent) had either no 
change or a  per cent reduction in number of seizures.
Dogs were being treated with a variety of ASDs. 
Fourteen out of  dogs were being treated with 
phenobarbital (range .–. g/mL) either 
alone or combined with KBr (range – mg/
dL), levetiracetam or imepitoin. In addition, ve dogs 
were being treated with imepitoin alone. Two dogs 
were treated with a combination of phenobarbital, 
levetiracetam and topiramate. Serum concentrations 
of phenobarbital, with or without KBr, were reported 
for  of  dogs. For those dogs, serum concentrations 
were unchanged at the end of the study compared with 
baseline.
QoL was reported as excellent (/) at the start of 
the study in  of the  dogs. In three dogs, the QoL 
was reported as very good, starting with a minimum of 
./. One dog was initially reported as poor (/), 
but was reported as / throughout the entire test 
phase, which coincidently was a cluster seizure dog 
that had a  per cent reduction in seizure rate. The 
majority of dogs (/) maintained the same level of 
QoL during the study.
Regarding the ataxia level, three owners reported 
mild ataxia (/ or /) at day , two of which 
improved during the study (ataxia level of / or / 
at day , respectively). One dog remained unchanged 
over the trial (/). Sedation was reported in  out of 
 dogs at day . Two dogs had a sedation level of /, 
four had a level of ≤/. At the end of the study (day 
), three dogs decreased the level of sedation, and 
three remained in the same level.
Finally, pet owner survey results indicated that  of 
 owners ( per cent) would recommend the diet for 
epileptic dogs. Of the veterinarians that responded to 
the survey,  ( per cent) would recommend the diet 
for epileptic dogs,  would not and  did not provide an 
answer.
Discussion
To expand the veterinary management options for 
canine patients with ASD treated IE, a commercially 
available diet enriched with . per cent MCT oil (as fed 
basis) plus a blend of other nutrients was offered to pet 
owners as an open- label feeding trial to prospectively 
evaluate seizure outcomes resulting from dietary 
management as an adjunct to ASD treatment. This study 
builds on existing canine research that demonstrated 
the clinical efficacy of a diet enriched with MCT oil in 
two double- blinded, placebo-  controlled, prospective 
diet clinical trial with a population of ASD(s)- resistant 
IE dogs.,  In the study by Law and others, the diet 
contained . per cent MCT oil (as fed basis) compared 
with . per cent added MCT oil in this current study. 
Previous unpublished work from Nestlé Purina 
revealed that ketone production is dose- dependently 
increased with MCT inclusion. However practically, the 
inclusion level of  per cent MCT oil (as fed basis) to 
a diet has limitations because of reduced palatability 
observations, as demonstrated in a study of the benefits 
of an MCT oil- enriched food fed to dogs with canine 
cognitive dysfunction syndrome.
Similarly, this compilation of case studies revealed 
that nearly  per cent of the study population ( of 
) became seizure free while on the commercial diet. 
This is similar to previous observations in which  
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per cent of dogs ( of ) were seizure free when fed a 
diet containing . per cent MCT oil, but experienced 
seizures when fed the placebo food absent of MCTs. 
Furthermore, this current data revealed a similar 
response rate of participants (. per cent;  of  dogs) 
to achieve > per cent seizure reduction (frequency 
and seizure day rate) when compared with the study 
population reported by Law and others, in which 
. per cent ( of  dogs) achieved > per cent 
reduction in seizure frequency and . per cent ( of 
) achieved > per cent reduction in seizure day rate. 
A more recent study used the direct supplementation of 
an MCT oil performed by the pet owner by adding on 
top and mixed in with their dog’s existing diet.  This 
MCT oil supplement trial included  dogs with IE and 
were provided supplementation equivalent to  per cent 
MCT oil as metabolic energy calculated. Most notable 
from this study was that only  per cent of the  dogs 
achieved more than  per cent seizure reduction or 
seizure freedom.
The observations of dietary eect of seizure reduction 
reported here are statistically signicant. Although, it is 
reasonable to consider important limitations to these 
results, as the number of animals involved in the study 
were not a large number of observations and around  
per cent of the eect seen could possibly be due to the 
placebo, regression to the mean, or Hawthorne eects. 
However, this multicentre eld study does conrm two 
former placebo-  controlled, double- blinded studies 
described above,  and the diet was well tolerated by 
most dogs, with  per cent of participating vets and 
 per cent of owners recommending to continue with 
the diet. It is also important to consider that there was 
an improvement in QoL and some of the side eects 
related to ataxia and sedation. From the ve dogs that 
experienced the onset of cluster seizures during the 
study period, the authors can remark that two of them 
decreased the number of seizures during the study, one 
showed no eect and the other two increased the number 
of seizures compared with day . In addition, there was 
no obvious trend on when these cluster seizures were 
observed during the diet phase, as two dogs had clusters 
during month two, whereas three dogs had clusters in 
month three. Ultimately, this study demonstrates that 
there was a similar signicant seizure reducing eect 
for IE dogs with single seizures, as well as for some dogs 
experiencing cluster seizures, as previously described 
in the other aforementioned published studies. In 
addition, these case studies conrm previous studies of 
feeding an MCT oil containing diet to dogs with IE is safe 
and tolerable, and with the available data, no change 
in ASD blood levels were recorded (data available from 
nine dogs) throughout the study.
This study diered in several distinguishing aspects 
from the former aforementioned studies and does 
have some additional limitations worth noting. The 
rst notable distinguishing factor is that multiple 
rst- opinion veterinary clinics participated in the 
recruitment and management of the patients that 
spanned over ve dierent countries across Europe, 
whereas the other study  was performed in a single 
referral hospital setting and conducted entirely through 
the Royal Veterinary College Clinical Investigation 
Center referral hospital in the UK. Secondly, the level 
of MCT oil (. per cent) diered relative to other 
studies referenced above. Thirdly, the recruited pet 
population was focused on a less severe type of IE with 
tier  diagnosis. And nally, to obtain clinically relevant 
data acquired by collaborating vets and their clients, 
the data represent a compilation of case studies, and 
consequently did not have a placebo-  controlled arm 
of the experimental design. A reasonable limitation 
underlying this study is based on the utilisation of an 
unblinded diet treatment experimental design that 
could impart a bias on the study participants, as well as 
because of recent reports of placebo eects. Many studies 
on epilepsy were designed to evaluate for a positive 
response to therapy, which is dened as a ≥ per cent 
reduction in seizures.   In one study which combines 
the results from three placebo- controlled trials, a large 
proportion of dogs with IE responded to placebo alone, 
with an approximately  per cent reduction in seizures 
following placebo administration.  However, the dogs 
in the placebo group were on conventional ASD therapy 
that could have aected the results and outcome. 
This placebo response has been attributed to the 
regression to the mean eect, the natural waxing and 
waning course of epilepsy over time, the likelihood for 
improved patient care during participation in the trial 
and investigator and participant bias. The presence of 
the strong placebo eect found in that report suggests 
that results from non- blinded studies, particularly 
those that involve a small number of animals and short 
follow- up time should be interpreted with some caution.
A further limitation to this study is the incomplete 
collection of blood samples for ASD monitoring from 
all dogs at both prefeeding and postfeeding time point, 
leaving open the fact that the authors could not clearly 
demonstrate ASD concentrations in the blood remained 
unchanged in all dogs throughout the study period. 
However in a previous clinical assessment of feeding 
a diet containing MCT oil to epileptic dogs, ASD levels 
were measured.  The ASD treatment regimens of the 
dogs remained the same between the placebo and 
MCT diet phases. There were no signicant changes in 
serum concentrations of phenobarbital (P=.) or 
KBr (P=.) between the placebo- standardised diet 
and MCT diet, respectively. Given that approximately 
 per cent ( out of ) of the dogs here showed no 
change in serum ASD level, and the prior ndings by 
Law and others, the authors would expect ASD serum 
concentrations in the other dogs were not altered. A 
nal limitation is that chloride content of the previous 
diets from the six pets receiving KBr treatment was 
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not specically measured before starting the trial 
to specically assess if therapeutic levels would be 
altered. However, for consistency across the study and 
consistency to previous clinical trials, all ASD regimens 
for all dogs were to remain unchanged throughout 
the study. It is also important to note that Purina Pro 
Plan NC NeuroCare has a chloride level of . g/ 
kcal. Although the authors do not have the information 
of the chloride level for the pretrial diets fed to the 
six dogs receiving KBr in the study, by estimating 
that maintenance diets may likely contain chloride 
levels around .–. g/ kcal, but could be as 
low as the minimum requirement of . g/ kcal 
(American Association of Feed Control Ocials, ). 
Thus, the test diet is at the high end of that range and 
consequently would have justied a potential elevation 
in KBr but would have confounded any observed diet 
eect.
The mechanism by which an MCT-  enriched diet 
provides clinical ecacy for some patients remains 
unclear, but it is likely a multifactorial modality that 
is underlying its eectiveness, such that MCTs and/
or their metabolites, in part, ameliorate some of the 
multiple metabolic dysfunctions that appears to be at 
the root of the disease.  The type of MCTs used in this 
current diet study are from the same MCT oil ingredient 
as previously used in IE dogs and with senior dogs to 
evaluate cognitive performance.   Initially in , 
a diet enriched with MCT oil was reported to improve 
cognitive performance in aged dogs, as demonstrated 
through a variety of neuropsychological tests.  The 
main mechanism of action proposed for these cognitive 
improvements was the generation of ketone bodies 
derived from the dietary source of MCTs,  as an 
alternative energy source for diminished brain energy 
metabolism that appears in aged dogs.  However, 
even though Law and others observed an increase in 
serum ketone concentrations in IE dogs fed the MCT oil- 
enriched diet, no relationship was observed between 
seizure frequency and serum ketones. This is in contrast 
to other evidence in children that suggests there is a 
direct relationship.  Alternatively, or in conjunction 
with ketones as an alternative energy source, MCTs 
may contribute to the maintenance of the neuronal 
structure via increasing concentrations of PUFA in the 
brain, which have also been shown to decrease as a 
consequence of ageing,  but this evidence is lacking in 
canine studies of IE.
In a recent study by a dierent laboratory, specic 
MCTs (decanoic acid) were fed to rodents and showed 
positive eects in seizure control,  where pathological 
mechanisms or pathways involved may be similar to the 
ones involved in ageing. A new mechanism of action 
proposed in rats for explaining the antiseizure eect of 
MCTs is a direct eect via blocking the AMPA receptors 
(responsible of the excitatory neurotransmission 
pathway) in the brain. This function has been proposed 
to be accomplished by the dietary medium chain fatty 
acid (MCFA) decanoic acid (C).  Other research as 
revealed that C and octanoic acid (C) fatty acids 
fed to rats increased the seizure threshold and induced 
sedation, and reported to be related to primarily C 
causing an increased passage of tryptophan (Trp) into 
the brain.  This anticonvulsant eect was abolished 
when Trp passage into the brain was blocked, thus 
ecacy of a ketogenic diet may be at least partly 
dependent on changes in Trp metabolism. Because 
rats serve as a model in human medicine as well as in 
veterinary medicine, this mechanism of action could 
possibly help explain the positive eects of MCTs on 
seizure frequency in dogs. Further studies should be 
conducted in order to conrm that this mechanism of 
action also occurs in dogs. Interestingly, recent canine 
serum metabolomics data generated during the clinical 
study reported by Law and others has indicated that 
IE dogs fed MCTs demonstrate global changes in 
lipid metabolism, and even provide initial evidence 
to suggest that C: moieties are involved in these 
metabolic pathways.
Conclusion
The data reported above are consistent with the positive 
effects (reduction in seizure frequency and days) of 
MCTs in dogs diagnosed with IE, in accordance with 
evidence in the published literature.   The diet used 
in the study has been shown to be very useful as an 
adjunct management strategy in dogs with IE. This is 
important because even with ASD treatment, more than 
two- thirds of dogs with IE have seizures long- term and 
about one- third of dogs with IE continue to experience 
seizures that are difficult to control.–  Thus, there 
is a great- unmet need to supply these canine patients 
with alternative and additional options to help support 
management of epilepsy, improve the QoL of the canine 
patients receiving ASDs, which will hopefully improve 
the QoL of the pet owners.
The palatability of the diet was good to excellent in 
the  per cent of the cases, which support the use of this 
type of MCTs in food for dogs. A survey of the vets and pet 
owners that participated in this study indicated that  
per cent of these vets and  per cent of owners would 
recommend the diet for epileptic dogs. These results are 
encouraging. However, larger randomised controlled 
trials with longer follow- up periods would be valuable 
and needed to understand the long- term benets of this 
type of diet on canine epilepsy management.
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